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Abstract
Background: For practical reasons it is not easy to obtain fasting samples in large population health surveys.
Non-fasting triglyceride (Tg) values are difficult to interpret. The authors compared the accuracy of statistically
corrected non-fasting Tg values with true fasting values and estimated the misclassification of subjects with high
low-density lipoprotein cholesterol (LDL-C) and the metabolic syndrome.
Methods: Non-fasting blood was obtained from a population-based sample of 4282 individuals aged 24-75 years
in the National FINRISK 2007 Study. Fasting blood samples were drawn from the same persons 3 months later.
Non-fasting serum Tg values were converted into fasting values using previously published formula. LDL-C was
calculated and classification of the metabolic syndrome was carried out according to three different latest
guidelines.
Results: The median (25
th, 75th percentile) non-fasting serum Tg concentration was 1.18 (0.87, 1.72) mmol/L and
after postprandial correction 1.06 (0.78, 1.52) mmol/L. The true-fasting serum Tg concentration was 1.00 (0.75, 1.38)
mmol/L (P < 0.001) vs. non-fasting and corrected value. Bias of the corrected value was +5.9% compared with the
true-fasting Tg. Of the true fasting subjects, 56.4% had LDL-C ≥3.00 mmol/L. When calculated using non-fasting
serum Tg, the prevalence of high LDL-C was 51.3% and using statistically corrected Tg it was 54.8%. The
prevalence of metabolic syndrome was 35.5% among fully fasted persons and among non-fasting subjects 39.7%,
which after statistical correction of Tg decreased to 37.6% (P < 0.001 for all comparisons).
Conclusions: Correction of non-fasting serum Tg to fasting values plays a minor role in population studies but
nevertheless reduces misclassification of calculated high LDL-C from 5.1 to 1.6% and the metabolic syndrome from
4.2 to 2.1%.
Background
For practical reasons fasting blood samples are difficult
to obtain in large population studies and thus such stu-
dies commonly comprise non-fasting or ‘semi-fasting’
blood samples [1-5]. For example, in a long series of
population-based studies in Finland since the early
1970s, a four hour fasting has been requested. Fasting is
not a necessary prerequisite for many analytes, but for
serum triglyceride (Tg) it is important [2,6]. Fasting
serum Tg values are needed for cardiovascular disease
risk evaluation [7,8] for the calculation of low-density
lipoprotein cholesterol (LDL-C) concentration and for
the classification of subjects into those with and without
metabolic syndrome [9-11]. However, non-fasting Tg has
emerged recently as an increasingly important risk factor
[12,13]. Also estimating trends in these risk factors has
become of utmost importance in epidemiology [14].
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ficiently fasted/postprandial serum Tg values can be
converted into “corrected” fasting values [15]. In view of
the potential error resulting from using non-fasting
serum Tg values in the calculation of LDL-C and conse-
quently in the classification of subjects into the meta-
bolic syndrome, we transformed non-fasting data to
fasting data using our recently published factors [15].
The aim of the present study was to assess how much
a corrected non-fasting serum Tg deviates from the true
fasting value and whether the correction for non-fasting
serum Tg is worthwhile for calculation of LDL-C or for
classifying subjects into the metabolic syndrome in
health examination surveys.
Methods
The National FINRISK 2007 Study (FR07) is the eight
consecutive population-based risk factor survey in Fin-
land. The surveys have been carried out with 5-year
intervals since 1972 and the sample sizes have varied
from 6500 to 13 500 men and women, depending on
the survey year. The total sample size of the FR07 study
was 9957 persons in the age range of 25-74 years. It was
a random sample, drawn from the population register
and stratified according to sex, 10-year age group and
five geographical areas. Of the 9957 invited persons,
6247 (62.7%) took part in both the health examination
and blood sampling [3].
During the year 2007 the same subjects participated in
health examinations twice. In January-April, subjects
were requested to fast for at least 4 hours before phle-
botomy. The participants of the surveys were asked the
time in full hours since their last meal by a study nurse.
For the present analysis (non-fasting FR07, visit 1) eligi-
ble were those who reported having fasted ≥2t o≤8
hours (1979 men) and ≥2t o≤7h o u r s( 2 3 0 3w o m e n )
based on our earlier work on effects of fasting on Tg
values [15]. In the substudy carried out in May-June the
same participants were requested to fast for 10 hours
(true-fasting FR07, visit 2).
In addition to the two groups described above, we
identified a separate group drawn from the FR07 sample
comprising 552 subjects who fulfilled the following fast-
ing criteria: ≥8 hours for men and ≥7h o u r sf o rw o m e n
in visit 1 and who had also participated in the true-fast-
ing study, i.e., visit 2. These subjects are referred to as
the Reference Group and they are not included in either
of the above parent population samples. Individuals with
serum Tg values >10 mmol/L were excluded from all
analyses.
In addition to reporting the results on all men and
women, we defined categories of healthy men (n = 824)
a n dw o m e n( n=9 9 4 )a st h o s ew h oh a daB M I≤35;
reported an alcohol consumption below the 90
th
percentile in self-reported questionnaire; had no diag-
nosed cardiovascular disease (CVD), diabetes or cancer;
had no medication for hypercholesterolemia; and had
normal blood pressure. The results are also presented
for subgroups with severe obesity BMI>35 (men n =
101, and women n = 183).
Subjects were classified into a high LDL-C group by
using the cut-off value ≥3.00 mmol/L calculated by the
Friedewald formula [16]. Subjects were classified as hav-
ing the metabolic syndrome according to three different
definitions [9-11].
Collection of blood and biomarker analyses
All laboratory measurements were carried out at the
D i s e a s eR i s kU n i to ft h eN a t i o n a lI n s t i t u t ef o rH e a l t h
and Welfare, Helsinki. The testing laboratory of the Dis-
ease Risk Unit (No. T077) is accredited by the Finnish
Accreditation Service, FINAS. Serum total cholesterol,
HDL-cholesterol and Tg concentrations were measured
from both non-fasting and true fasting blood samples
and plasma glucose concentrations were measured from
true fasting blood samples only.
Venous blood samples were drawn in a sitting position
with a light stasis into a tube containing clot activator
(Vacuette, Greiner Bio-One, Frickenhausen, Germany)
in visit 1 (non-fasting study) and (Venosafe, Terumo
Europe, Leuven, Belgium) in visit 2 (true fasting study)
for the lipid assays and into a fluoride-citrate tube
(Venosafe) for the glucose assay. Serum and plasma
were separated by centrifuging at 2200 g within 1 hour
of collection for 10 minutes at room temperature. Con-
s e q u e n t l ys e r u ma n dp l a s m aw e r ea l i q u o t e di n t ob a r -
code-labelled tubes and stored locally at a minimum
temperature of -20°C and transported frozen to the
laboratory once a week and stored at -70°C for analyses.
All measurements were performed within one month
from the blood draw on a clinical chemistry analyzer,
Architect c8000 (Abbott Laboratories, Abbott Park, IL,
USA). Total cholesterol, HDL-cholesterol, Tg and glu-
cose concentrations were determined enzymatically
using commercial reagents from Abbott Laboratories.
For standardising the measurements, the laboratory
has taken part in the Lipid Standardization Program
organised by the Centers for Disease Control and Pre-
v e n t i o n( C D C ) ,A t l a n t a ,U S Aa n dE x t e r n a lQ u a l i t y
Assessment Schemes organised by Labquality, Helsinki,
Finland. During the course of the study comprising 6
months in 2007, the precision between series expressed
as coefficient of variation (CVa) was less than 1.5% for
all analytes except for HDL-cholesterol whose mean
CVa was 2.3%. The mean (SD) systematic errors (bias)
were 0.8% (0.5%) for total cholesterol, -0.6% (1.4%) for
HDL-cholesterol, -1.1% (1.2%) for Tg and 0.0% (2.7%)
for glucose.
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The statistical analyses were done using Microsoft Excel
Analyse-it software, Stata statistical package 10.1 (Stata-
Corp. 2007. Stata Statistical Software: Release 10.1. Col-
lege Station, TX; StataCorp LP.) and IBM SPSS Statistics
19. The bias comparisons were carried out using the
Altman-Bland method [17] and shown as mean and
95% confidence intervals (95% CI), Figure 1. Serum Tg
was expressed as mean, median and 25
th and 75
th per-
centiles. Significance for the differences between groups
was analyzed using the Wilcoxon matched-pairs signed-
rank test and differences between prevalences by chi-
square test. We considered a P value less than 0.05 as
statistically significant. The total intraindividual biologi-
cal variation, CV
2
tb =C V
2
anal +C V
2
biol [18] for Tg was
calculated using Tg concentrations for the reference
group from the two visits and for the whole group (n =
4282) from the non-fasting and true fasting visits.
Non-fasting serum Tg values were converted individually
into corresponding fasting Tg values using the correction
factors published previously [15]. The correction factors
for the subgroups were per hour of fasting, 3.7% (all), 4.3%
(healthy) and 6.5% (BMI>35). The correction was calcu-
lated until 8 hours for men and until 7 hours for women.
Ethical issues and information protection
The population health surveys were approved by the
Ethical Committee of the Hospital District of Helsinki
and Uusimaa. All participants gave their written
informed consent prior to participation in the study.
The information protection rules in the National
Institute for Health and Welfare (former National Public
Health Institute to 2009) were followed throughout.
Results
Figure 1 shows the Altman-Bland plot indicating a 5.9%
(95% CI: 4.8-7.0) bias between the difference of cor-
rected FR07 and true-fasting data for serum Tg. Also,
illustrated by the figure, the magnitude of the bias does
not seem to depend on the Tg concentration. Figure 2
shows the distribution for raw data (all) (visit 1) before
and after correction for non-fasting serum Tg concen-
trations of the subjects (n = 4282) and the true-fasting
data (visit 2) of the same subjects.
The medians (25
th,7 5
th percentiles) of the non-fasting
and corrected Tg data were 1.18 (0.87, 1.72) mmol/L (P
< 0.0001) and 1.06 (0.78, 1.52) mmol/L (P < 0.0001)
compared to the median of the true-fasting value, 1.00
(0.75, 1.38) mmol/L, Additional file 1. The median
serum Tg concentrations of the non-fasting data differed
significantly from true-fasting values for all groups,
Additional file 1. After correction the corrected medians
differed significantly from the true fasting medians for
all subjects, all men, all women and healthy men, Addi-
tional file 1. The within sub-group difference between
corrected and true-fasting median serum Tg was largest
among all men 10.2% (P < 0.0001). In the reference
group, in which all subjects had fasted for at least 7
hours at both visits (n = 552), the difference between
the two visits was less than 2%, Additional file 2.
Biological variation
The mean (25
th,7 5
th percentiles) total intraindividual
biological variation (CVtb) of serum Tg of the reference
group (n = 552) and the whole group (n = 4282) were
17.1% (6.5, 23.9) and 21.9% (8.3, 31.5), respectively. The
corresponding mean CVtb values of serum total choles-
terol were 6.1% (2.2, 8.1) and 6.2% (2.3, 8.4).
Effect of triglyceride correction on the prevalence of high
LDL-cholesterol
Among the 4282 subjects in the true-fasting sampling (visit
2), 56.4% had an LDL-C value ≥3.00 mmol/L. The propor-
tion of high LDL-C in FR07 calculated using non-fasting
(visit 1) serum Tg values was 51.3% and using statistically
corrected serum Tg values 54.8% (P < 0.0001 for all com-
parisons). In the 7- or 8-hour fasting reference group, visit
1 (n = 552) the proportion of subjects with an LDL-C
value ≥3.00 mmol/L was 58.5% and the respective value of
the 10-hour fasting reference group, visit 2 was 57.1%.
Effect of triglyceride correction on the prevalence of the
metabolic syndrome
The metabolic syndrome (Tg ≥ 1.7 mmol/L) according
to the National Cholesterol Education Program 2005
Figure 1 Altman Bland plot of the differences between serum
triglycerides of the non-fasting visit 1 with correction and the
true fasting visit 2. The lines describe identity (solid thin line), bias
between results (solid thick line), 95% limits of agreement of bias
(dashed line) and 95% confidence intervals of bias and limits of
agreement (dotted lines).
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2 in 1918 subjects (35.5%). In the non-fasting subjects
the proportion was 39.7%, which after correction for
postprandial serum Tg decreased to 37.6% (difference
between prevalences P < 0.0001). In the reference sub-
group, which had fasted at both visits, the prevalences
were 35.9% (198 subjects) in visit 1 and 36.4% (201 sub-
jects) in visit 2.
Based on criteria of the International Diabetes Federa-
tion (MS-IDF) [10] and the International Diabetes Fed-
eration Task Force (MS-IDFTF) [9] the prevalences
were 47.1% and 49.8% in visit 1, 44.8% and 46.3% in
visit 2 and 45.6% and 47.9% after statistical correction of
serum Tg in visit 1, respectively (P < 0.0001 for all
respective comparisons). Misclassification due to use of
non-fasting vs. corrected Tg concentrations in calcula-
tion of prevalences decreased from 4.2% (metabolic syn-
d r o m ev i s i t2 - v i s i t1 )t o2 . 1 %( v i s i t2 - c o r r e c t e dv i s i t1 )
using the MS-ATP criteria. Likewise, misclassification
using the MS-IDF or MS-IDFTF criteria improved from
2.3% to 1.5% and 2.5% to 1.9%, respectively.
Discussion
In population health examination surveys standardiza-
tion and long-term quality assessment of risk factor
measurements are essential. Especially so in monitoring
trends and tracking of risk factors [3,5,19]. Among the
major risk factors for CVD, serum Tg has emerged
recently as an increasingly important risk factor
[7,12,13,20,21]. In both diagnostics and risk assessment
fasting serum Tg concentration is required either for
the calculation of LDL-C or classification of subjects
into the metabolic syndrome. In large population-based
health examination surveys true fasting for all subjects is
often difficult to achieve [1-5,22] and usefulness of
undefined post prandial serum Tg data is doubtful. In a
previous study, we calculated factors by which non-fast-
ing serum Tg values can be converted into fasting values
when the time from the last meal is known [15].
I nt h ep r e s e n ts t u d yw ew a n t e dt ot e s tw h e t h e rt h e
statistical correction of non-fasting serum Tg into fast-
ing values is worthwhile in calculating LDL-C and cate-
gorizing subjects into the metabolic syndrome. Our data
showed that using incomplete fasting serum Tg concen-
tration to calculate LDL-C concentration results in
misclassification of 5.1% of subjects as having an LDL-C
below 3.00 mmol/L compared to true fasting values.
Correction of post prandial serum Tg narrowed misclas-
sification to 1.6%, increasing the number of subjects at
risk by some tens of thousands at the population level
in Finland. Likewise, categorizing subjects for the meta-
bolic syndrome by the MS-ATP-2005 [11] criteria using
corrected non-fasting Tg instead of the non-fasted values,
decreased the proportion of misclassification and resulted
in virtually the same prevalence as the use of true-fasting
serum Tg, the difference being 2.1 percentage units.
Figure 2 Distribution of serum triglyceride results of the non-fasting visit 1, the true fasting visit 2 (panel A) and the corrected non-
fasting visit 1 (panel B). The vertical dotted lines describe means.
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criteria the differences were very similar.
The total intraindividual biological variation of fasting
serum Tg in the reference group was 17.1%, which is
much narrower than in other similar studies [23] but
the total biological variation in our original samples
(21.9%) was of the same order of magnitude as found by
others, 21.7 - 29.9% [18], having a time frame of months
between the phlebotomies. The small effects of non-fast-
ing vs. fasting serum Tg on misclassification into high
LDL-C or metabolic syndrome should be compared to
the intraindividual biological variation of serum Tg.
Because of the high biological variation of serum Tg
several measurements of Tg per subject are needed for
reliably estimating the CVD risk [7,23].
In addition to its use as a risk factor, serum Tg con-
centration is used widely to calculate LDL-C with the
Friedewald formula [16]. Because of limitations of the
formula [24], the new recommendation from the
National Cholesterol Education Program (NCEP)
encourages direct measurement of LDL-C. Increasing
concerns have, however, been raised about the specifi-
city of different direct methods for measuring the cho-
lesterol concentration from various lipoprotein fractions.
The newly published data showed [25] that all evaluated
direct LDL-C methods failed to meet the NCEP’st o t a l
error goals when analysing samples from patients with
cardiovascular disease or dyslipidemia. Recent data have
proved that the number of LDL particles is a more reli-
able indicator for cardiovascular risk assessment than
the cholesterol concentration in lipoprotein particles
[26]. Because there is only one apolipoprotein B (apoB)
molecule per one LDL particle, measurement of apoB
gives an estimate of the number of lipoprotein particles.
Therefore, it has been suggested that, to improve CVD
risk assessment, apoB measurement should be adopted
in addition to LDL-C to national guidelines [27]. Imple-
mentation of such a measure would benefit greatly large
surveys, since measurement of apoB does not require a
fasting blood sample.
Conclusions
Our data based on a random population sample of 4282
individuals examined twice within a 3 month interval
showed that measuring serum Tg after an incomplete fast
causes a relatively small misclassification of the prevalence
of people with high LDL-C or metabolic syndrome.
Additional material
Additional file 1: Triglyceride medians and means with and without
correction among non-fasting subjects and among true fasting
subjects. Wilcoxon matched-pairs signed-ranks test values for the
differences between the groups. Abbreviations: BMI, body mass index;
FR07, FINRISK-2007 Study; P, probability.
aP-value without is comparison
of non-fasting without correction with true fasting, with is comparison of
non-fasting with correction with true fasting.
Additional file 2: Triglyceride medians and means, number and
proportions of high LDL-C (>3.00 mmol/L) and high triglyceride
(>1.70 mmol/L) concentrations in the different groups. Abbreviations:
FR07, FINRISK-2007 Study; LDL-C; Low-Density Lipoprotein Cholesterol; N,
Number of Subjects; Tg, Triglyceride.
aP < 0.0001 compare to true fasting.
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